Αρχική World News Delayed irAEs Occur in a Small Subset of Patients with Melanoma, but...

Delayed irAEs Occur in a Small Subset of Patients with Melanoma, but Often High Grade and Difficult to Manage

An analysis of data from 20 international centres, published on 30 March 2021 in the Annals of Oncology, shows that delayed immune-related adverse events (irAEs) occur in a small subset of patients with melanoma. However, delayed irAEs are often high grade and difficult to manage, frequently requiring extended course of systemic corticosteroids or additional immunosuppression and can lead to death. Delayed irAEs are more likely to occur in those patients who continue anti-PD1 therapy, but those who stop anti-PD1 remain at risk and can occasionally present with severe irAEs long after stopping the treatment.

The authors wrote in the study background that although many patients have few irAEs with anti-PD1 therapy, severe irAEs can still occur. irAEs typically develop within 4 to 6 months after starting immunotherapy. irAEs onset up to 1 year is also described, with new-onset occurring less frequently beyond 1 year. However, real-world data suggest that delayed irAEs may be more frequent, with a rate of 43% in patients remaining on anti-PD1 therapy beyond 2 years. The occurrence of irAEs >90 days after stopping immunotherapy has been described anecdotally. Since most clinical trials report severe adverse events up to 90 days after the last dose of immunotherapy at most, such delayed irAEs after stopping anti-PD1 therapy are not captured in trial data.

The incidence of delayed irAEs, defined by the study team as those with onset more than 1 year after staring the anti-PD1 therapy, is not known. It is not clear whether most delayed irAEs occur in patients who remain on anti-PD1 therapy, or how commonly these occur after stopping treatment. How long patients remain at risk of irAE following cessation of immunotherapy is not defined as well.

The aim of the study was to estimate the incidence of delayed irAEs in melanoma patients treated with anti-PD1 therapy and describe their characteristics and management. The incidence of delayed irAEs was estimated as a proportion of melanoma patients treated with anti-PD1 therapy and surviving longer than 1 year. The study team examined onset, clinical features, management and outcomes of irAEs.

In total, 118 identified patients developed 140 delayed irAEs, of which 20 were after initial combination with anti-CTLA4 therapy; an estimated incidence was 5.3% (95% confidence interval [CI] 4.0-6.9).

The median onset of delayed irAE was 16 months (range, 12-53). In total, 87 patients (74%) were on anti-PD1 therapy at irAE onset, 15 patients (12%) were less than 3 months from last dose, 16 patients (14%) were more than 3 months from last dose of anti-PD1 therapy.

The most common delayed irAEs were colitis, rash and pneumonitis with 55 of all irAEs (39%) being grade 3 or higher. Steroids were required in 80 patients (68%), as well as an additional immunosuppressive therapy in 27 patients (23%).

There were two irAE-related deaths, encephalitis with onset during anti-PD1 therapy, and a multiple organ-irAE with onset 11 months after ceasing anti-PD1 therapy.

Early irAEs appearing less than 12 months had also occurred in 69 patients (58%), affecting a different organ from the delayed irAE in 59 patients (86%).

The authors underlined that further work is required to identify patients who are most at risk of delayed irAEs. It is important that clinicians and patients are aware of these risks when make decisions about therapy continuation.


Owen C, Bai X, Quah T, et al. Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. Annals of Oncology; Published online 30 March 2021. DOI: https://doi.org/10.1016/j.annonc.2021.03.20



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...